Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company products are sold in countries around the world. Eli Lilly products include neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health products.
Website: lilly.com


  • Good financial results growth rate 44.0% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (27.6%)
  • Dividend yield for the last twelve months 0.7%
  • Free cash flow yield -1.7% (LTM)
  • Share price is 161.7% higher than minimum and 19.2% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (46.1x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $1.7 mln (0.000% of cap.)

Key Financials (Download financials)

Ticker: LLY
Share price, USD:  (-0.4%)775.775
year average price 831.90  


year start price 892.15 2024-07-04

max close price 960.02 2024-08-30

min close price 713.71 2025-05-23

current price 775.78 2025-07-03
Common stocks: 900 605 000

Dividend Yield:  0.7%
FCF Yield LTM: -1.7%
EV / LTM EBITDA: 46.1x
EV / EBITDA annualized: 44.3x
Last revenue growth (y/y):  +45.2%
Last growth of EBITDA (y/y):  +42.9%
Historical revenue growth:  +20.4%
Historical growth of EBITDA:  +34.8%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 698 667
Net Debt ($m): 35 377
EV (Enterprise Value): 734 044
EBITDA LTM ($m): 15 914
EV / LTM EBITDA: 46.1x
Price to Book: 49.3x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-06-28fool.com

Which Stock Will Dominate the Weight Management Market Through 2030?

2025-06-26reuters.com

Lilly to launch Mounjaro pen in India to compete with Novo's Wegovy

2025-06-25seekingalpha.com

Buy Eli Lilly While The Market Hesitates And Let Time Make You Dominate

2025-06-25news.sky.com

Weight loss and diabetes jabs linked to potentially fatal side effect

2025-06-25cnbc.com

Healthy Returns: New weight loss drug data show Eli Lilly is gaining ground

2025-06-25fool.com

3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow

2025-06-24seekingalpha.com

Eli Lilly: It Is A Bet On Human Longevity

2025-06-23prnewswire.com

Lilly declares third-quarter 2025 dividend

2025-06-23seekingalpha.com

Eli Lilly and Company (LLY) Presents at Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference Transcript

2025-06-22prnewswire.com

Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data